Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Innocan Pharma Corp
(CSE:
INNO
)
0.2500
UNCHANGED
Official Closing Price
Updated: 9:55 AM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Innocan Pharma Corp
CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark
May 28, 2024
Innocan Pharma's Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance.
Via
Benzinga
This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
April 23, 2024
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration...
Via
Benzinga
Exposures
Product Safety
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
April 02, 2024
Innocan Pharma's 2023 earnings report: Revenue soars 534%, operating loss down 61%, $1.5M capital raise. CEO shares strategic vision.
Via
Benzinga
CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
February 13, 2024
Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are...
Via
Benzinga
Exposures
Product Safety
Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024
December 22, 2023
This month, the Indigenous Cannabis Industry Association held its first Indigenous Cannabis Regulators roundtable, bringing together Indigenous Cannabis Regulators from Tribal Nations and...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It
October 23, 2023
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has closed the second and final tranche of its previously announced private placement offering of its units.
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Product Safety
CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare
September 21, 2023
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has entered into an agreement with Research Capital Corporation as the sole agent and sole book-runner on a "best efforts" agency basis...
Via
Benzinga
Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
August 28, 2023
Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug delivery platforms,
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.